Strategic financing Recent equity financing of 5M signals growth funding and a pathway to scale commercialization of the MemorEM TEMT device, presenting a sales opportunity to partner on clinical deployment, payer discussions, and in-clinic adoption programs.

Clinical stage leverage MemorEM device has progressed through preclinical and clinical studies with claims of immune balance and potential cognitive benefits, creating a revenue potential through neurologist and memory disorder specialist channels once FDA pivotal trial milestones are reached.

Awards momentum Industry recognition such as the Tampa Bay Inno Award enhances credibility with potential customers and hospital systems, aiding outreach to early adopters, key opinion leaders, and patient advocacy groups.

Non-invasive tech appeal Non-invasive in-home TEMT technology positions NeuroEM as a patient-friendly option, enabling partnerships with clinics, home health services, and remote monitoring platforms to expand patient access and service lines.

Market focus Target market includes Alzheimer’s and neurodegenerative conditions with a drug-free approach, offering opportunities to present at conferences, engage with neurodegenerative disease programs, and pursue pilot deployments in memory clinics and neurology practices.